Capital Fund Management (CFM)
DNLI icon

Capital Fund Management (CFM)’s Denali Therapeutics DNLI Stock Holding History

Capital Fund Management (CFM)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,871
Closed -$306K – 2506
2025
Q2 		$306K Buy
+21,871
New +$308K ﹤0.01% 2271
2022
Q2 		– Sell
-13,443
Closed -$432K – 1483
2022
Q1 		$432K Sell
13,443
-360
-3% -$12.4K ﹤0.01% 1334
2021
Q4 		$616K Sell
13,803
-3,202
-19% -$152K ﹤0.01% 1403
2021
Q3 		$858K Buy
17,005
+5,204
+44% +$293K 0.01% 1241
2021
Q2 		$926K Sell
11,801
-40,518
-77% -$2.51M 0.01% 1173
2021
Q1 		$2.99M Buy
+52,319
New +$3.5M 0.03% 599

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Fund Management (CFM)'s DNLI Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 21,871 shares — an estimated $306K sold.

Capital Fund Management (CFM) first reported a position in DNLI in Q1 2021 and held it in 6 quarters. The position peaked at $2.99M in Q1 2021. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 21,871 Denali Therapeutics shares in Q3 2025, an estimated $306K.
  • Capital Fund Management (CFM) first reported a position in Denali Therapeutics in Q1 2021 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Denali Therapeutics position peaked at $2.99M in Q1 2021.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.